Module

Monitoring Response, Prediction Methodology, Staging, and Imaging in Prostate Cancer

Source: Prostate Cancer Annual Update 2006

Monitoring Response, Prediction Methodology, Staging, and Imaging in Prostate Cancer

Program Director: E. David Crawford, MD

Faculty:
Mack Roach III, MD

CME CREDIT INFORMATION

Release Date: 03/22/06

Expiration Date: 03/21/07

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain the utility of various PSA measures in assessing present and future risk of prostate cancer
Describe the utility of nomograms for assessment of indolent disease
Discuss the strengths and weaknesses of current staging and imaging techniques and their accuracy in stratifying patients with newly diagnosed prostate cancer

Topics covered include:

Introduction
PSA for Monitoring Treatment Response
Prediction Methodology
Staging Systems for Prostate Cancer
Stratification With Nomograms
Stratification Based on Other Predictive Models
Biopsies Following Treatment: The Utility of Gleason Grading
Image Fusion of MRI or CT With Indium-III Capromab Pendetide Data
Stratification With Imaging
Computer-Simulated Transperineal Prostate Biopsy
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.